NICE endorsement for Eylea a boost for Bayer

23 January 2018

German pharma major Bayer (BAYN: DE) received good news from the UK on Tuesday in the shape of positive guidance from the National Institute for Health and Care Excellence (NICE) that underlines the value of Eylea (aflibercept solution for injection) as a treatment for people with wet age-related macular degeneration (AMD).

The clinical guideline reconfirms the current NICE technology appraisals for Eylea, which is licensed in the UK to treat a number of eye conditions, and therefore the continued availability of this medicine on the National Health Service for appropriate patients.

Clear recommendations are made in the new guidance for the timely referral of patients with AMD, which is vital to maintaining the highest quality of life for patients with this sight-threatening condition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK